Our data support the early, guideline-directed use of GLP-1 RAs in patients with T2DM with excess weight, with attention to gender, the patient’s HbA1c at the baseline, and adherence as key factors. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.